Global Coronary Intravascular Lithotripsy (IVL) Market, By Device Type (Coronary Intravascular Lithotripsy (IVL) Balloon Catheters, Intravascular Lithotripsy (IVL) Control Consoles), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By Application (Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD)), By Technology (Single-Use Systems, Multi-Use Systems), By Patient Age Group (Adult, Pediatric), By Distribution Channel (Direct Sales, Retail sales) – Industry Trends and Forecast to 2031.

Coronary Intravascular Lithotripsy (IVL) Market Analysis and Size

Global coronary intravascular lithotripsy (IVL) market collectively are estimated to affect around 5%-10% of the population in the U.S. Some autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have prevalence rates closer to 1%, while others, such as hashimoto's thyroiditis and type 1 diabetes, are more common, affecting up to 2%-3% of the population.

Data Bridge Market Research analyses that the global coronary intravascular lithotripsy (IVL) market which was USD 258.70 million in 2023, expected to reach the value of 459.32 million by 2031, and is expected to undergo a CAGR of 7.44% during the forecast period. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Coronary Intravascular Lithotripsy (IVL) occur when the body's immune system mistakenly attacks its own tissues, organs, or cells, leading to inflammation, tissue damage, and dysfunction. Autoimmune disease diagnosis refers to the process of identifying and confirming the presence of autoimmune disorders in individuals. Diagnosing autoimmune diseases typically involves a combination of medical history evaluation, physical examination, laboratory tests, imaging studies, and sometimes tissue biopsies. The global coronary intravascular lithotripsy (IVL) market is for improving patient outcomes by facilitating early detection, accurate diagnosis, and personalized treatment strategies for individuals affected by autoimmune disorders for appropriate treatment planning, disease management, and monitoring of autoimmune diseases to improve patient outcomes and quality of life.

Global Coronary Intravascular Lithotripsy (IVL) Market Dynamics

Drivers

• Advancement in Diagnostic Technologies

Continuous innovation in coronary intravascular lithotripsy (IVL) technologies represents a key driver for market growth. Ongoing research and development efforts focus on enhancing the efficacy, safety, and applicability of IVL devices. Technological advancements aim to refine the precision of lithotripsy, ensuring more targeted and effective treatment of coronary artery diseases. Improvements in device design, imaging capabilities, and treatment algorithms contribute to an overall better patient experience and outcomes. As these innovations continue to unfold, they not only address existing challenges but also pave the way for broader market acceptance and sustained growth.

• Increasing Cardiovascular Disorders

The escalating prevalence of cardiovascular diseases is a significant factor propelling the demand for advanced treatments such as coronary intravascular lithotripsy (IVL). With a global rise in conditions such as coronary artery disease, there is a growing need for innovative and effective interventions. IVL, as a minimally invasive and precise technique, meets this demand by providing a targeted solution for treating calcified coronary lesions. The expanding patient pool with cardiovascular disorders drives the adoption of IVL technologies, contributing substantially to the overall expansion of the market. As the burden of cardiovascular diseases continues to grow, IVL plays a pivotal role in meeting the evolving healthcare needs and preferences of patients and healthcare providers alike.

Opportunities

• Strategic Collaborations Between Healthcare Organizations

Strategic collaborations between healthcare organizations and technology developers in the global coronary intravascular lithotripsy (IVL) market can catalyze innovation and research and development initiatives. By pooling expertise and resources, such partnerships facilitate the exploration of novel technologies, refinement of existing solutions, and the development of more advanced and patient-friendly IVL procedures. Collaborations may also streamline the regulatory process, ensuring that new innovations adhere to industry standards and swiftly reach the market. These synergies between healthcare entities and technology developers enhance the overall landscape of IVL, fostering a dynamic environment conducive to breakthrough.

• Integration of Global Increase in the Aging Population

The global increase in the aging population represents a significant driver for the global coronary intravascular lithotripsy (IVL) market. As individuals age, there is a heightened susceptibility to cardiovascular diseases, including coronary artery diseases. This demographic shift creates a substantial market opportunity for IVL technologies, as they offer minimally invasive solutions for treating coronary blockages in elderly patients. The demand for effective and less invasive procedures aligns with the preferences of the aging population, contributing to the growth of the IVL market.

Restraints/Challenges

• High Cost of Equipment

The adoption of coronary intravascular lithotripsy (IVL) technology faces a significant challenge due to the substantial initial investment and ongoing operational costs associated with acquiring IVL equipment. The sophisticated nature of this technology, aimed at treating coronary artery diseases, often results in higher procurement costs. In resource-constrained healthcare settings, where budget constraints are prevalent, the financial burden posed by expensive IVL equipment can impede its widespread adoption. This challenge underscores the importance of exploring cost-effective solutions, subsidies, or alternative financing models to make IVL technology more accessible to a broader range of healthcare facilities.

• Limited Awareness

Another crucial restraint to the widespread adoption of IVL technology is the limited awareness among both healthcare professionals and patients regarding the procedures and benefits associated with IVL. Lack of familiarity with this innovative treatment approach may lead to hesitation in its incorporation into clinical practices. To overcome this obstacle, there is a pressing need for targeted education and training initiatives. These efforts should aim not only at healthcare professionals, ensuring they are well-versed in IVL procedures, but also at patients to increase awareness and foster confidence in the efficacy and safety of this advanced medical technology.

Recent Developments

• AVS announced the closing of USD 8.8 million in new funding, bringing its Series B funding round to USD28.8 million. The funding will continue to support clinical trials of the company's pulsed intravascular lithotripsy (PIVL) device in peripheral settings, while also advancing preclinical research to expand indications in coronary cases. In September 2022, AVS successfully enrolled, processed and collected favorable 30-day follow-up data from patients in the first-in-human POWER PAD I clinical trial. Prospective, multicenter, single-arm feasibility study evaluated the technical and clinical effectiveness of the PULSETM IVL System in the treatment of patients with femoral popliteal artery calcification
• Shockwave Medical, Inc. announced full commercial product availability in the U.S. for the Shockwave L6 peripheral IVL catheter following FDA clearance. The Shockwave L6 catheter is specifically designed to correct calcification of refractory lesions in large peripheral vessels, including the common iliac and femoral arteries. Calcification of these arteries is common and is associated with decreased procedural success and increased complications with intravascular techniques

Global Coronary Intravascular Lithotripsy (IVL) Market Scope

The global coronary intravascular lithotripsy (IVL) market is segmented on the basis of device type, end user, application, technology, patient age group, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Device Type

• Coronary Intravascular Lithotripsy (IVL) Balloon Catheters
• Intravascular Lithotripsy (IVL) Control Consoles

End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Application

• Coronary Artery Disease (CAD)
• Peripheral Artery Disease (PAD)

Technology

• Single-Use Systems
• Multi-Use Systems

Patient Age Group

• Adult
• Pediatric

Distribution Channel

• Direct Sales
• Retail sales

Global Coronary Intravascular Lithotripsy (IVL) Market Regional Analysis/Insights

The global coronary intravascular lithotripsy (IVL) market is analyzed and market size insights and trends are provided by country, device type, end user, application, technology, patient age group, and distribution channel as referenced above.

The countries covered in the global coronary intravascular lithotripsy (IVL) market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.

North America region dominates the global coronary intravascular lithotripsy (IVL) market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of patients.   

Asia-Pacific region is expected to witness significant growth during the forecast period of 2024 to 2031 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global coronary intravascular lithotripsy (IVL) market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global coronary intravascular lithotripsy (IVL) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global coronary intravascular lithotripsy (IVL) market.

Competitive Landscape and Autoimmune Disease Diagnosis  Market Share Analysis

The global coronary intravascular lithotripsy (IVL) market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global coronary intravascular lithotripsy (IVL) market.

Some of the major players operating in the global coronary intravascular lithotripsy (IVL) market are:

• Cardiovascular Systems, Inc. (U.S.)
• Abbott (U.S.)
• Siemens (Germany)
• Olympus America (U.S.)
• Boston Scientific Corporation (U.S.)
• Medispec (U.K.)
• Dornier MedTech (Germany)
• ELMED Medical Systems (Turkey)